Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 0.59 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149415 | 1.00 | ERN1 (0.59) | ERN1TLR2TLR1TLR6PRKDC | |
| Isovanillin SCHEMBL3664249 | 0.87 | ALDH1A1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5069879 | 0.85 | ERN1 (0.58) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL1527154 | 0.82 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3747172 | 0.80 | ERN1 (0.45) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL31366778 | 0.80 | NFE2L2 (0.54) | ERN1ALDH1A1 | |
| SCHEMBL30928251 | 0.80 | NFE2L2 (0.54) | ERN1ALDH1A1 | |
| SCHEMBL148284 | 0.79 | PRKDC (0.48) | ERN1TLR2TLR1TLR6PRKDC | |
| SCHEMBL13605931 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL8043039 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981939-B2 | Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2011-07-19 | — | — | US | disclosed |
| US-20110098362-A9 | Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098362-A9 | Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization | BCL2, BCL2L2, BAD | ERN1 4304/4885TLR2 461/4885TLR1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.